Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Gabriella Lionetto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4635-3680; OpenAlex author ID A5089615706. Sources: OpenAlex.

Their work

Papers
30 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
161
Papers, trials and grants by year

2021: 2 papers · 2022: 2 papers · 2023: 3 papers · 2024: 6 papers · 2025: 6 papers · 2026: 11 papers

Papers 30

  1. The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Co-author DOI 10.1002/gin2.70074↗
  2. Discovering Hereditary Risk Through Surveillance: A Prospective Genetic Analysis of Individuals With Familial Pancreatic Cancer. Co-author DOI 10.1002/ueg2.70187↗
  3. Upfront surgery vs. neoadjuvant therapy in pancreatic cancer with venous involvement: a multicenter retrospective analysis. Co-author DOI 10.1007/s00423-026-04291-0↗
  4. Pancreatic cancer surgery in Italy: an updated snapshot from a national multicentre analysis of outcomes by hospital volume. Co-author DOI 10.1007/s13304-026-02813-5↗
  5. Benefit of adjuvant chemotherapy for resected pancreatic cancer following neoadjuvant FOLFIRINOX or Gemcitabine-Nab-paclitaxel: a multinational analysis. Co-author DOI 10.1093/jnci/djag235↗
  6. Lymph Node Yield Is Associated With Improved Overall Survival and Increased Time to Recurrence in Node-Negative Pancreatic Ductal Adenocarcinoma Following Neoa… Co-author DOI 10.1097/sla.0000000000006432↗
  7. Morphologic Characterization of Pancreatic Ductal Adenocarcinoma following Post-neoadjuvant Pancreatectomy and Clinical Value of Intratumor Heterogeneity. Co-author DOI 10.1097/sla.0000000000006565↗
  8. Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. Co-author DOI 10.1245/s10434-026-19218-8↗
  9. ASO Visual Abstract: Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. Co-author DOI 10.1245/s10434-026-19370-1↗
  10. Interpreting Circulating Bile Acid Profiles in Pancreatic Cancer: The Role of Cholestasis and Its Management. Co-author DOI 10.3390/cancers18152481↗
  11. Correction: Danese et al. Interpreting Circulating Bile Acid Profiles in Pancreatic Cancer: The Role of Cholestasis and Its Management. Cancers 2026, 18, 2481. Co-author DOI 10.3390/cancers18193144↗
  12. Pancreatic cancer and long survivors: a survey of Italian society of oncological surgery (SICO). Co-author DOI 10.1007/s13304-024-02039-3↗
  13. Local ablation disrupts immune evasion in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2024.217327↗
  14. Resection to Exploration Ratios and Associated Outcomes in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000006197↗
  15. Reappraising the Role of Intraoperative Neck Margin Revision in Postneoadjuvant Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Multi-institution… First author DOI 10.1097/sla.0000000000006322↗
  16. Carbohydrate Antigen 19-9 Delta Function for Survival Prediction in Borderline Pancreatic Cancer. A PANC-PALS Consortium International Multicenter Derivation a… Co-author DOI 10.1097/sla.0000000000006735↗
  17. Surgical and Oncological Outcomes of Minimally Invasive Left Pancreatectomy for Pancreatic Cancer: Robotic vs. Laparoscopic Approach. First author DOI 10.3390/curroncol32070376↗
  18. Futility of Up-Front Resection for Anatomically Resectable Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2024.2485↗
  19. Surveillance of Individuals at High Risk of Developing Pancreatic Cancer: A Prevalence Meta-analysis to Estimate the Rate of Low-yield Surgery. Co-author DOI 10.1097/sla.0000000000006094↗
  20. Cure Probabilities After Resection of Pancreatic Ductal Adenocarcinoma: A Multi-Institutional Analysis of 2554 Patients. Co-author DOI 10.1097/sla.0000000000006166↗
  21. Adjuvant Therapy After Upfront Resection of Resectable Pancreatic Cancer: Patterns of Omission and Use-A Prospective Real-Life Study. Co-author DOI 10.1245/s10434-024-14951-4↗
  22. Outcomes of a 3-Year Prospective Surveillance in Individuals at High Risk of Pancreatic Cancer. Co-author DOI 10.14309/ajg.0000000000002546↗
  23. Cellular collusion: cracking the code of immunosuppression and chemo resistance in PDAC. Co-author DOI 10.3389/fimmu.2024.1341079↗
  24. A dynamic analysis of empirical survival outcomes after pancreatectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2022.11.015↗
  25. Pathological staging in postneoadjuvant pancreatectomy for pancreatic cancer: implications for adjuvant therapy. Co-author DOI 10.1093/bjs/znad146↗
  26. CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal… Co-author DOI 10.1245/s10434-022-12622-w↗
  27. The prognostic role of fatigue, depression and anxiety on postoperative outcomes after pancreatectomy for pancreatic cancer. A prospective observational study … Co-author DOI 10.1016/j.pan.2022.10.001↗
  28. Importance of Nodal Metastases Location in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: Results from a Prospective, Lymphadenectomy Protocol. Co-author DOI 10.1245/s10434-022-11417-3↗
  29. Laser Treatment of Pancreatic Cancer with Immunostimulating Interstitial Laser Thermotherapy Protocol: Safety and Feasibility Results From Two Phase 2a Studies. Co-author DOI 10.1016/j.jss.2020.10.027↗
  30. Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial. Co-author DOI 10.1016/j.pan.2021.06.005↗

Closest collaborators

The 25 strongest of 161 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Roberto Salvia · 24 shared papers, 2021–2026 · strength 4.51
  2. Giuseppe Malleo · 22 shared papers, 2021–2026 · strength 4.03
  3. Salvatore Paiella · 15 shared papers, 2021–2026 · strength 2.71
  4. Fabio Casciani · 12 shared papers, 2022–2026 · strength 2.39
  5. Massimo Falconi · 11 shared papers, 2023–2026 · strength 2.02
  6. Alessandro Esposito · 9 shared papers, 2021–2026 · strength 1.94
  7. Matteo De Pastena · 8 shared papers, 2021–2026 · strength 1.85
  8. Claudio Bassi · 11 shared papers, 2021–2025 · strength 1.64
  9. Giulio Belfiori · 8 shared papers, 2023–2026 · strength 1.54
  10. Stefano Crippa · 8 shared papers, 2023–2026 · strength 1.54
  11. Claudio Luchini · 8 shared papers, 2022–2026 · strength 1.50
  12. Aldo Scarpa · 7 shared papers, 2022–2026 · strength 1.21
  13. Antonio Pea · 4 shared papers, 2023–2026 · strength 0.90
  14. Laura Maggino · 5 shared papers, 2022–2026 · strength 0.83
  15. Erica Secchettin · 5 shared papers, 2021–2026 · strength 0.81
  16. Giulia Gasparini · 4 shared papers, 2023–2026 · strength 0.75
  17. Paola Mattiolo · 4 shared papers, 2023–2026 · strength 0.74
  18. Francesco DE COBELLI · 3 shared papers, 2026 · strength 0.65
  19. Riccardo Casadei · 4 shared papers, 2024–2025 · strength 0.64
  20. Carlos Fernández-del Castillo · 3 shared papers, 2023–2026 · strength 0.63
  21. Cristina Rosa Ferrone · 3 shared papers, 2023–2026 · strength 0.63
  22. Domenico Tamburrino · 3 shared papers, 2025–2026 · strength 0.61
  23. Giuseppe Lippi · 2 shared papers, 2026 · strength 0.60
  24. Elisa Danese · 2 shared papers, 2026 · strength 0.60
  25. Motaz Qadan · 2 shared papers, 2025–2026 · strength 0.49

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.